[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huashan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":606},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,71,0,25,[9,40,61,84,100,121,141,168,194,215,240,267,295,323,351,373,401,422,448,471,492,513,540,560,587],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644819","exploratory-study-on-infection-and-immunosenescence-based-on-an-elderly-clinical-cohort-100644819",false,"NCT07672522","Exploratory Study on Infection and Immunosenescence Based on an Elderly Clinical Cohort","Inclusion Criteria for the Healthy Control Group\n\n1. No clinical symptoms suggestive of infection, including fever, cough, dyspnea, fatigue, or myalgia.\n2. No abnormal physical signs, including lymphadenopathy, hepatomegaly, splenomegaly, or skin rash.\n3. Normal laboratory test results, including complete blood count (CBC), C-reactive protein (CRP), and liver and renal function tests.\n4. Healthy adults without underlying chronic diseases, no history of infectious diseases within the previous 6 months, and generally normal cognitive function.\n5. Male or female.\n6. Able to understand the study procedures and voluntarily provide written informed consent.\n\nInclusion Criteria for the Infection Group 1.Age: 60 years or older; no gender restrictions. 2. Clinically diagnosed with an infectious disease by the treating physician. 3. The participant provides informed consent and signs the relevant documents.\n\n\\-------------- Exclusion Criteria for the Healthy Control Group\n\n1. Refusal to participate in the study;\n2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nExclusion Criteria for the Infection Group\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, tumor, or other conditions).\n2. Positive culture results are determined by the clinician to be due to colonization or contamination rather than infection.\n3. Refusal to participate in the study.\n4. Patients in critical or severe conditions who are unable to cooperate with sample collection.\n5. Other conditions deemed unsuitable for inclusion as determined by the researchers.",true,"ALL","60 Years",{"count":20,"type":21},484,"ESTIMATED","5 Years","OBSERVATIONAL","This prospective observational cohort study aims to investigate the relationship between immunosenescence and infectious diseases in older adults. Individuals aged 60 years and older, including elderly patients with infections and healthy controls, will be enrolled and followed longitudinally.\n\nClinical information, laboratory test results, and health assessment data will be collected. Biological specimens, including peripheral blood, urine, stool, sputum, and nasopharyngeal swabs, will be obtained during enrollment and follow-up. Participants will undergo regular assessments of health status, infection events, and aging-related clinical characteristics.\n\nThe study will evaluate age-related changes in immune function, immune cell composition, immune receptor repertoires, epigenetic characteristics, metabolic profiles, and respiratory and gut microbiota. By integrating clinical and multi-omics data, the study aims to identify biomarkers associated with immunosenescence, susceptibility to infection, disease severity, and clinical outcomes in older adults.\n\nThe results are expected to improve understanding of the mechanisms linking aging, immune dysfunction, and infectious diseases, and to support the development of predictive models and preventive strategies for infection management and healthy aging in elderly populations.",[26],"Immunosenescence","RECRUITING","2026-06-26",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":31},"2024-11-29",{"date":35,"type":21},"2029-10-30",{"name":37,"class":38},"Huashan Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100643096","research-project-on-the-interaction-between-immune-function-and-infectious-diseases-in-older-adults-and-the-development-of-prevention-and-control-strategies-100643096","NCT07644962","Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies","Inclusion Criteria:\n\n\\- General Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.\n2. Male or female.\n3. Able to understand the study and voluntarily provide written informed consent.\n\nInfection Cohort Inclusion Criteria\n\n1. Adults aged 60 years or older, regardless of sex.\n2. Patients with an infectious disease diagnosed by a qualified clinician.\n\nExclusion Criteria:\n\n* General Cohort Exclusion Criteria\n\n  1. Refusal to participate in this study.\n  2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.\n\nInfection Cohort Exclusion Criteria\n\n1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).\n2. Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.\n3. Refusal to participate in this study.\n4. Critically ill patients or those unable to cooperate with specimen collection procedures.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.",{"count":47,"type":21},23000,"As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.\n\nBuilding upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.",[50,26,51],"Infectious Diseases","Aging","NOT_YET_RECRUITING","2026-06-08",{"date":55,"type":31},"2026-06-12",{"date":57,"type":21},"2026-06-09",{"date":59,"type":21},"2029-12-30",{"name":37,"class":38},{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":39},"100643786","phase-2-vertebrobasilar-dolichoectasia-treatment-with-amiloride-100643786","NCT07634068","Vertebrobasilar Dolichoectasia Treatment With Amiloride","Vertebrobasilar Dolichoectasia Treatment With Amiloride: a Pilot Study Based On 5.0 T MRI","Inclusion Criteria:\n\n1. Age≥18 years, any gender;\n2. Patients with VBD confirmed by DSA\u002FCTA\u002FMRA;\n3. No history of VBD rupture and no surgical treatment for VBD;\n4. mRS\\\u003C4;\n5. Positive plasma SGK1;\n6. No history of posterior circulation stroke, and no symptoms or signs related to VBD;\n7. No need for subsequent use of antiplatelet or statin drugs;\n8. Capable of signing an informed consent form with the accompaniment and understanding of a guardian.\n\nExclusion Criteria:\n\n1. History of malignant tumors, systemic lupus erythematosus, or gout;\n2. Pregnancy or lactation;\n3. Amiloride or sulfonamide allergy;\n4. Hydrocephalus requiring urgent surgical intervention or respiratory failure requiring life support treatment;\n5. Abnormal hepatic and\u002For renal function (serum transaminase \\> 40 U\u002FL; serum creatinine \\> 110 μmol\u002FL); and\u002For abnormal white blood cells\u002Fplatelets (white blood cells count \\\u003C 3.5 × 10⁹\u002FL or \\> 9.5 × 10⁹\u002FL; platelets count \\\u003C 100 × 10⁹\u002FL or \\> 300 × 10⁹\u002FL); hyperkalemia, hypokalemia, hyponatremia, or hypercalcemia;\n6. Acute cerebral infarction within the last month or definite high signal on DWI indicating acute or subacute cerebral infarction;\n7. Acute stage of intracranial hemorrhage as indicated by CT;\n8. History of VBD rupture or surgery;\n9. Presence of acute active infection (such as severe bacterial, viral or fungal infection);\n10. Uncontrolled diabetes (HbA1c≥7%);\n11. Need for subsequent use of antiplatelet or statin drugs;\n12. Systolic blood pressure\\\u003C 90 mmHg or\u002Fand diastolic blood pressure\\\u003C 60 mmHg;\n13. Currently participating in other clinical studies;\n14. Presence of contraindications for MRI examination;\n15. Other situations not suitable for inclusion.","18 Years",{"count":70,"type":21},6,"INTERVENTIONAL",[73],"PHASE2","The aim of this pilot study is to assess the efficacy of amiloride in reducing wall enhancement in vertebrobasilar dolichoectasia(VBD) on high-resolution magnetic resonance vessel wall imaging(HR-VWI) via anti-inflammatory mechanisms, clarify the efficacy of amiloride in delaying the progression of VBD, evaluate the safety of amiloride in the treatment of VBD.",[76],"Vertebrobasilar Dolichoectasia","2026-06-03",{"date":53,"type":31},{"date":80,"type":21},"2026-06",{"date":82,"type":21},"2027-12",{"name":37,"class":38},{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":71,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":99,"locationsCount":39},"100643320","phase-2-vertebrobasilar-dolichoectasia-treatment-with-sirolimus-100643320","NCT07634120","Vertebrobasilar Dolichoectasia Treatment With Sirolimus","Vertebrobasilar Dolichoectasia Treatment With Sirolimus: a Pilot Trial Based On 5.0 T MRI","Inclusion Criteria:\n\n1. Age≥18 years, any gender;\n2. Patients with VBD confirmed by DSA\u002FCTA\u002FMRA;\n3. No history of VBD rupture and no surgical treatment for VBD;\n4. mRS\\\u003C4;\n5. Positive plasma SGK1;\n6. History of posterior circulation infarction or accompanied by VBD-related symptoms\u002Fsigns;\n7. Currently and in the future, need to take antiplatelet and statin drugs simultaneously, or currently and in the future, do not need to take antiplatelet and statin drugs;\n8. Capable of signing an informed consent form with the accompaniment and understanding of a guardian.\n\nExclusion Criteria:\n\n1. History of malignant tumors;\n2. Pregnancy or lactation;\n3. Sirolimus allergy;\n4. Hydrocephalus requiring urgent surgical intervention or respiratory failure requiring life support treatment;\n5. Abnormal hepatic and\u002For renal function (serum transaminase \\> 40 U\u002FL; serum creatinine \\> 110 μmol\u002FL); and\u002For abnormal white blood cells\u002Fplatelets (white blood cells count \\\u003C 3.5 × 10⁹\u002FL or \\> 9.5 × 10⁹\u002FL; platelets count \\\u003C 100 × 10⁹\u002FL or \\> 300 × 10⁹\u002FL);\n6. History of immunosuppressive therapy;\n7. Acute cerebral infarction within the last month or definite high signal on DWI indicating acute or subacute cerebral infarction;\n8. Acute stage of intracranial hemorrhage as indicated by CT;\n9. History of VBD rupture or surgery;\n10. Presence of acute active infection (such as severe bacterial, viral or fungal infection);\n11. Uncontrolled diabetes (HbA1c≥7%);\n12. History of liver or lung transplantation;\n13. Presence of organic heart disease;\n14. History of arteriovenous thrombosis;\n15. Patients taking only antiplatelet drugs or only statin drugs;\n16. Patients taking or needing to take CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, telithromycin, ritonavir, atazanavir, diltiazem, verapamil, cyclosporine, amiodarone, sildenafil, grapefruit juice, etc.) or CYP3A4 inducers (rifampicin, rifabutin, phenobarbital, phenytoin, carbamazepine, dexamethasone, St. John's wort, etc.);\n17. Currently participating in other clinical studies;\n18. Presence of contraindications for MRI examination;\n19. Other situations not suitable for inclusion.",{"count":92,"type":21},12,[73],"The aim of this pilot trial is to assess the efficacy of sirolimus in reducing wall enhancement in vertebrobasilar dolichoectasia(VBD) on 5 T high-resolution magnetic resonance vessel wall imaging(HR-VWI) via anti-inflammatory mechanisms, clarify the efficacy of sirolimus in delaying the progression of VBD, evaluate the safety of sirolimus in the treatment of VBD.",[76],{"date":53,"type":31},{"date":80,"type":21},{"date":82,"type":21},{"name":37,"class":38},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":68,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100636864","identification-and-molecular-characterisation-of-urban-environmental-stress-patterns-affecting-mental-illness-100636864","NCT07571226","Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness","Inclusion Criteria:\n\n1. Diagnosis: The primary diagnosis meets the DSM-IV criteria for depressive disorder, generalized anxiety disorder, or alcohol use disorder, and comorbid conditions may be present;\n2. Patients with mental disorders aged 18-60 years, with a balanced gender ratio;\n3. Normal intelligence and ability to use a smartphone running the Android operating system;\n4. Willingness to wear a wristband equipped with physiological monitoring functions (such as heart rate and electrodermal activity), download the study application, and upload data during the study period;\n5. Participants with depression or generalized anxiety disorder who are taking medication must be on a single stable dose of a selective serotonin reuptake inhibitor (SSRI), specifically citalopram or escitalopram, and this medication regimen must have been maintained for at least 5 days. Participants with alcohol use disorder who are taking medication have no restriction on the type of drug, but the medication regimen should also have been maintained for at least 5 days. At baseline assessment, patients with depression or anxiety disorders should have a Hamilton Depression Rating Scale (HAMD-17) score \\>7 or a Hamilton Anxiety Rating Scale (HAMA-14) score \\>7.;\n6. Voluntary participation in this study and signing of informed consent;\n7. For patients with alcohol use disorder (AUD): AUD patients must have successfully completed alcohol withdrawal, confirmed by clinical standards or relevant healthcare professionals.\n\nInclusion Criteria for Healthy Control Group\n\n1. Healthy subjects aged 18-60 years, with a balanced gender ratio;\n2. Normal intelligence and ability to use a smartphone running the Android operating system;\n3. Willingness to wear a wristband equipped with physiological monitoring functions (such as heart rate and electrodermal activity), download the study application, and upload data during the study period;\n4. Voluntary participation in this study and signing of informed consent.\n\nExclusion Criteria:\n\n1. Currently taking opioid medications;\n2. Receiving any form of brain stimulation therapy within the past 1 month (including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other similar treatments);\n3. Skin infection or severe skin damage on the wrist or upper limbs that may affect the normal use of monitoring devices;\n4. Recent use (within 30 days) of medications that may interfere with drug metabolism, such as strong CYP450 inhibitors\u002Finducers;\n5. Severe physical diseases (such as brain tumors or injuries) or special conditions (such as current pregnancy or lactation) that may affect the study protocol;\n6. HAMD-17 item 3 (suicide) \\>3 points (severe suicidal behavior);\n\nExclusion Criteria for Healthy Control Group\n\n1. Currently using benzodiazepines or opioid medications;\n2. Currently receiving any form of brain stimulation therapy (including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other similar treatments);\n3. Skin infection or severe skin damage on the wrist or upper limbs that may affect the normal use of monitoring devices;\n4. Recent use (within 30 days) of medications that may interfere with drug metabolism, such as strong CYP450 inhibitors\u002Finducers, or not reaching steady-state drug concentration before the study;\n5. Severe physical diseases (such as brain tumors or injuries) or special conditions (such as current pregnancy or lactation) that may affect the study protocol.",{"count":107,"type":21},680,"Mental disorders have become a major contributor to the global burden of non-communicable diseases, with disability-adjusted life years (DALYs) attributable to these conditions continuing to rise. Although evidence suggests that environmental factors may account for up to 40% of the attributable risk for mental disorders such as major depressive disorder, anxiety disorders, and alcohol use disorder, the underlying mechanisms remain unclear, particularly regarding how dynamic environmental stress influences disease onset, progression, and relapse. Traditional research has primarily focused on individual-level psychosocial factors, including socioeconomic status and life events, while lacking real-time, multidimensional assessments of objective urban environmental stressors such as air pollution, noise exposure, and reduced green space.\n\nThis study proposes a prospective longitudinal cohort design based in real-world environments, enrolling both patients with mental disorders and healthy controls. Using wearable devices integrated with the \"'StreetMind'\" mobile application and wear the visible watch, we will continuously and dynamically collect multimodal data on environmental exposures and physiological responses in urban settings. These include photoplethysmography (PPG)-derived heart rate, oxygen saturation, physical activity, and gait parameters, as well as objective environmental indicators such as temperature, humidity, light intensity, and noise levels. At baseline, all participants will undergo standardized psychiatric assessments to characterize depressive, anxiety, and addictive conditions. Peripheral blood and urine samples will also be collected for subsequent molecular and multi-omics analyses.\n\nThe study aims to systematically evaluate the associations between urban environmental factors-including air pollution, noise exposure, and green space availability-and the risk of mental disorder relapse. Furthermore, it seeks to elucidate the potential mechanisms by which environmental stress affects mental health through neuroinflammation and alterations in brain circuitry. The findings are expected to provide novel insights for risk prediction, early intervention, and precision management of mental disorders.",[110,111,112],"Major Depressive Disorder (MDD)","Anxiety Disorder","Alcohol Use Disorder (AUD)","2026-05-31",{"date":77,"type":31},{"date":116,"type":31},"2026-04-10",{"date":118,"type":21},"2029-05-30",{"name":37,"class":38},3,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":129,"studyType":23,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100640317","multi-center-validation-study-of-a-large-language-model-based-intelligent-agent-for-blood-cell-analysis-100640317","NCT07607184","Multi-center Validation Study of a Large Language Model-based Intelligent Agent for Blood Cell Analysis","Inclusion Criteria:\n\n* Subjects who underwent routine blood tests in the outpatient, emergency, or inpatient departments of the participating centers during the study period.\n\nCorresponding samples must have complete instrument results, review trails, and report timestamp records.\n\nApproved for inclusion by the Ethics Committee.\n\nExclusion Criteria:\n\n* Samples collected during periods of instrument malfunction or interface transmission anomalies.\n\nMissing key research data, particularly samples where the final review conclusion or key timestamps cannot be confirmed.\n\nSubjects or their legal representatives explicitly refuse to participate in the study.",{"count":128,"type":21},20000,"1 Year","I. Study Background: Currently, in most medical institutions, the review of blood cell analysis still heavily relies on manual verification by laboratory staff. This process requires a comprehensive analysis of instrument parameters, alarm flags, historical comparison results, and, when necessary, microscopic examination. However, with the increasing volume of test samples and the high concentration of review tasks during peak hours, the traditional manual review model increasingly shows problems such as prolonged turnaround time (TAT), uneven workload distribution, and decreased consistency in reviews. In recent years, intelligent review systems based on Large Language Models (LLM) have shown potential in analyzing abnormal results and stratifying sample risks by integrating preset rules, clinical diagnostic information, and multi-dimensional laboratory data, which is expected to optimize the review workflow.\n\nII. Study Objective: To evaluate the difference in overall sample review turnaround time between the experimental process and the control process during the formal study phase, and to test its superiority.\n\nIII. Subjects: The investigators need to recruit approximately 20,000 subjects, regardless of age or gender.\n\nIV. Study Procedures: If participants agree to participate in the study, participants only need to allow us to use participants test results after participants have completed your routine blood test (CBC).\n\nV. Risks and Benefits:\n\n1. Risks: This study poses no risk to the subjects. The investigators only use the result data of patients after participants have had their routine blood test; there is no need for patients to undergo additional blood draws.\n2. Benefits: It will shorten the turnaround time for routine blood test results and share the workload of doctors in reviewing these results.\n\nVI. Privacy: All of participants information will be kept strictly confidential and will only be used for this scientific research.",[132],"Complete Blood Count Review","2026-05-24",{"date":135,"type":31},"2026-05-28",{"date":137,"type":21},"2026-05-14",{"date":139,"type":21},"2027-08-31",{"name":37,"class":38},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":155,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100640904","artificial-intelligence-driven-tuberculosis-landscape-analysis--stratification-research-100640904","NCT07611695","Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research","TB-ATLAS","Inclusion Criteria for Model Development Cohort:\n\n* Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who received TB treatment;\n* Initiation of TB treatment on or after January 1, 2021;\n* Complete key diagnosis and treatment data available in the electronic medical record system.\n\nInclusion Criteria for External Validation Cohort:\n\n* Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who is planning to start TB treatment;\n* Voluntary participation with signed informed consent form (for adults ≥18 years); parental \u002F guardian consent and co-signed informed consent form are required for minors aged ≤ 18 years.\n\nExclusion Criteria:\n\n* Co-morbidity confounding: the presence of other active, life-threatening disease (e.g. late-stage malignancy, non-HIV severe immunodeficiency) for which the expected survival or priority of treatment may substantially interfere with the attribution of TB treatment outcomes;\n* Extremely poor treatment adherence: documented evidence indicating that the patient either never initiated treatment or was permanently lost to follow-up within the early treatment period (\\\u003C2 weeks), precluding the collection of any valid outcome data.",{"count":149,"type":21},31600,"The goal of this observational study is to establish and validate a comprehensive AI-driven clinical decision support system (AI-CDSS) in whole-chain management for pulmonary tuberculosis (TB) patients. The main question it aims to answer is:\n\nHow is the predictive performance of this system in terms of multiple key links during TB diagnosis and treatment? Can real-world benefits be derived from this system? This AI framework supports clinicians in making smarter decisions, ultimately improving cure rates and ensuring that every patient receives the most effective, personalized care possible.",[152,153,154],"Pulmonary Tuberculosis","Tuberculosis (TB)","Tuberculosis Active",[156,157,158,159],"tuberculosis","artificial intelligence","predictive model","clinical decision support system","2026-05-20",{"date":135,"type":31},{"date":163,"type":21},"2026-06-01",{"date":165,"type":21},"2028-06-30",{"name":37,"class":38},2,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":71,"phases":177,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":39},"100546961","the-effectiveness-and-safety-of-body-posture-in-preventing-postoperative-recurrence-for-chronic-subdural-hematoma-100546961","NCT06401772","The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma","The Effectiveness and Safety of Body Posture to Improve Intracranial Pressure in Preventing Postoperative Recurrence for Chronic Subdural Hematoma (BP-CSDH) -A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. chronic subdural hematoma is diagnosed with CT\u002FMRI scan; thickness of hematoma is more than 1 cm;\n2. more than 60 years of age or 60 years;\n3. MGS-GCS (Markwalder's Grading Scale and Glasgow Coma Scale) is less than or equal to 2;\n4. patients have neurological symptom caused by CSDH before surgery, such as headache, dizziness, nausea, vomiting, numbness or weakness of limb, instability to walk, unconsciousness, trouble speaking, insensitive, etc.\n5. receive burr hole drainage;\n6. sign informed consent voluntarily.\n\nExclusion Criteria:\n\n1. have brain hernia or acute massive cerebral infarction that have to perform craniotomy\n2. have severe malignancies, hemorrhagic disease, cardiac dysfunction and other serious disease that may impede recovery or follow-up compliance;\n3. Spinal deformities (e.g., kyphosis) or psychiatric disorders precluding prolonged body posture therapy adherence\n4. Concomitant severe intracranial tumors, aneurysms, or vascular malformations that may impede recovery.\n5. Patients with cranial CT demonstrating no significant compression or displacement of brain tissue, asymptomatic presentation, and unaffected daily activities were deemed ineligible for surgical intervention by neurosurgeons;\n6. CSDH persisting for over 1 year and exhibiting marked organization\u002Fsolidification of the hematoma;\n7. CSDH caused by over V-P shunting;\n8. during burr hole drainage, patients have to perform craniotomy due to acute bleeding or brain hernia;\n9. Intraoperative complications (e.g., cerebral contusion, intraparenchymal catheter placement) during burr hole drainage;\n10. have deep venous thrombosis of lower extremity or pulmonary embolism;\n11. cannot complete regular reexamine within 1 year for any reason;\n12. life expectancy less than 1 year;\n13. participating other ongoing clinical trial;\n14. patients are not qualified for other reason evaluated by two neurosurgeons;\n15. have bile reflux gastritis and esophageal diseases.",{"count":176,"type":21},830,[178],"NA","This study aims to investigate the effectiveness and safety of body posture to improve intracranial pressure in preventing postoperative recurrence for chronic subdural hematoma",[181,182],"Chronic Subdural Hematoma","Recurrence",[181,184,185],"body posture","intracranial pressure","2026-04-26",{"date":188,"type":31},"2026-04-30",{"date":190,"type":31},"2024-08-08",{"date":192,"type":21},"2028-01",{"name":37,"class":38},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":16,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":71,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":4},"100635446","impact-of-hand-rub-placement-on-patient-trust-and-disease-stigma-100635446","NCT07552792","Impact of Hand Rub Placement on Patient Trust and Disease Stigma","The Impact of Hand Rub Placement on Hand Hygiene Sequence, Patient Trust, and Disease Stigma: A Randomised Controlled Trial","Inclusion Criteria:\n\nFor Patients:\n\n* Aged 18 years or older.\n* Diagnosed with psoriasis and receiving treatment at the designated psoriasis specialty outpatient clinic during the study period.\n* Legally capable of signing the informed consent form and cognitively able to understand and complete the questionnaire (independently or with assistance from family members).\n\nFor Physicians:\n\n* Hold a registered practicing qualification in the Dermatology Department of Huashan Hospital Pudong Branch and are qualified for independent outpatient consultations.\n* Scheduled to continuously undertake outpatient work in the designated consultation rooms during the study period.\n* Voluntarily sign the informed consent form for behavioral observation.\n\nExclusion Criteria:\n\nFor Patients:\n\n* Severe visual, hearing, or speech impairments leading to basic doctor-patient communication barriers.\n* Diagnosed with psychiatric disorders (e.g., schizophrenia, severe depression) that, as assessed by a specialist, may interfere with the authenticity of the questionnaire responses.\n* Presenting with a clinical state requiring emergency treatment during the visit, such as acute infection of skin lesions or generalized pustules.\n\nFor Physicians:\n\n* Non-permanent practicing staff of the hospital, such as visiting physicians or rotating medical students.\n* Unable to independently perform hand hygiene procedures due to physical\u002Flimb dysfunction.",{"count":202,"type":21},250,[178],"This study aims to investigate how the physical placement of hand sanitizer in consultation rooms affects patient trust and feelings of disease stigma. While hand hygiene is an essential infection control measure in healthcare, performing it immediately in front of patients with visible, non-communicable conditions (such as psoriasis) might inadvertently make patients feel rejected or stigmatized.This study uses a randomized controlled design to evaluate if a simple environmental modification-changing the spatial location of the hand sanitizer-can naturally nudge physicians to alter their hand hygiene timing without compromising safety. Researchers will discreetly observe the hand hygiene behavior of outpatient dermatologists and ask participating psoriasis patients to complete a brief, anonymous questionnaire regarding their trust in the physician, feelings of stigma, and overall satisfaction with the consultation. The goal is to provide evidence for patient-centered hospital space designs that protect patient psychological well-being while maintaining hygiene standards.",[206,207],"Noncommunicable Disease","Psoriasis","2026-04-20",{"date":210,"type":31},"2026-04-27",{"date":212,"type":21},"2026-05-01",{"date":80,"type":21},{"name":37,"class":38},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":71,"phases":224,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":39},"100634318","early-phase-1-evaluating-safety-tolerability-and-preliminary-efficacy-of-ysch-01-monotherapy-and-in-combination-with-atezolizumab-for-recurrent-glioblastoma-100634318","NCT07538128","Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma","An Open-Label, Single-Center, Multiple-Dose Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab in the Treatment of Recurrent Glioblastoma","Inclusion Criteria\n\nParticipants must meet all the following criteria to be enrolled in this study:\n\n1. Age \\> 18 years, male or female.\n2. Expected survival ≥ 12 weeks.\n3. Karnofsky Performance Status (KPS) score ≥ 70 at baseline.\n4. Histopathologically confirmed glioblastoma (GBM), with first recurrence after prior surgery, chemotherapy, and\u002For radiotherapy.\n5. Presence of 1 contrast-enhancing tumor lesion (diameter 1-4 cm) assessed by MRI during the screening phase.\n6. Eligibility for tumor biopsy and Ommaya reservoir implantation based on hematological, hepatic, renal, and coagulation function parameters.\n7. Recovery from toxic effects of prior chemo\u002Fradiotherapy (CTCAE ≤ Grade 1, except for special cases like alopecia or pigmentation), with the Investigator determining that the corresponding adverse events (AEs) pose no safety risk.\n8. Eligible subjects of reproductive potential (male and female) must agree to use effective contraception during the trial and for at least 6 months after the last dose.\n\nExclusion Criteria\n\nParticipants with any of the following conditions are ineligible for enrollment:\n\n1. History or current evidence of another primary malignancy.\n2. Known allergy to the study drug or any of its excipients, or a history of unexplained severe allergic reactions.\n3. Any contraindication to gadolinium-enhanced MRI, such as presence of a pacemaker, infusion pump, or allergy to MRI contrast agents.\n4. Tumor involvement of the brainstem, cerebellum, or spinal cord; or leptomeningeal disease.\n5. MRI evidence of tumor enhancement extending to the ventricular wall, or the tumor cavity is fused with the ventricle after surgery.\n6. Preoperative MRI assessment showing the Ommaya puncture path traverses the ventricles.\n7. Active infection requiring intravenous antibiotic therapy, or unexplained fever (body temperature ≥37.5°C).\n8. Uncontrolled systemic diseases or relevant medical history, including: diabetes mellitus, cardiovascular\u002Fcerebrovascular disease (e.g., heart failure ≥NYHA Class II, hypertension ≥Grade 2, ≥First-degree atrioventricular block, history of myocardial infarction, myocarditis), pulmonary insufficiency, thyroid dysfunction, cerebral infarction within the past 6 months.\n9. Active autoimmune disease or history of autoimmune disorders (e.g., ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, Wegener's granulomatosis).\n10. Plan or requirement to receive any live vaccine during the screening or treatment phase.\n11. Other conditions assessed as incompatible with intravenous administration of Atezolizumab.",{"count":223,"type":21},10,[225],"EARLY_PHASE1","The clinical study of YSCH-01 will adopt an open-label, randomized design, with a planned enrollment of 10 participants with recurrent glioblastoma. Participants will be randomly allocated to the YSCH-01 monotherapy cohort or the YSCH-01 + Atezolizumab combination cohort, with 5 participants in each cohort. The study consists of the following three phases: screening phase, treatment phase, and follow-up phase. The primary endpoint is the 1-year survival rate of participants",[228],"Recurrent Glioblastoma",[230,228,231,232],"YSCH-01","Adenovirus","Atezolizumab","2026-04-13",{"date":208,"type":31},{"date":236,"type":31},"2025-01-09",{"date":238,"type":21},"2027-02-28",{"name":37,"class":38},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":71,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":39},"100630003","phase-2-sglt2i-improve-left-atrial-function-in-patients-with-paroxysmal-atrial-fibrillation-hypertension-and-abnormal-glucose-metabolism-100630003","NCT07482020","SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism","A Randomized Controlled Trial of SGLT2 Inhibitors to Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation and Comorbid Hypertension and Abnormal Glucose Metabolism","Inclusion Criteria:\n\n* • Patients aged 18-80 years, treated in the outpatient or inpatient departments of each research center and included in the AF database.\n\n  * Patients with paroxysmal AF confirmed by 12-lead electrocardiogram, 24-hour Holter monitoring, or handheld electrocardiogram devices.\n  * Patients with hypertension who have already started antihypertensive treatment.\n  * Patients with diabetes who have already started antidiabetic treatment, or patients with prediabetes who have not received antidiabetic treatment but have an HbA1c level within the range of 6.1-6.4% in the past three months.\n\nExclusion Criteria:\n\n* • Atrial fibrillation caused by severe mitral stenosis.\n\n  * Atrial fibrillation with severe mitral regurgitation and severe tricuspid regurgitation.\n  * Patients who have been clinically diagnosed with heart failure (heart failure with preserved ejection fraction or heart failure with reduced ejection fraction).\n  * Special types of cardiomyopathy: amyloid cardiomyopathy, Fabry disease, muscular dystrophy, hypertrophic obstructive cardiomyopathy, etc.\n  * Patients with a history of myocardial infarction within the past three months.\n  * Pregnant women.","80 Years",{"count":249,"type":21},66,[73],"Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared to those without heart failure. Abnormal left atrial function is an important mechanism leading to the occurrence of AF-related heart failure. Therefore, it is essential to find drugs that can improve left atrial function to prevent heart failure in patients with AF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are important drugs for regulating metabolic abnormalities. Studies have found that these drugs also reduce the risk of new-onset AF in patients with heart failure. Thus, the investigators hypothesize that SGLT2i may be able to regulate left atrial function.\n\nThis study is a multicenter randomized controlled trial using three-dimensional speckle tracking echocardiography to investigate whether SGLT2i can improve left atrial function and prevent heart failure in patients with paroxysmal AF who have hypertension and metabolic disorders, compared to placebo. The investigators also observed the effects of SGLT2i on cardiovascular and metabolic risk factors. The investigator team has a solid foundation in the field of cardiovascular metabolism, having completed the evaluation of left atrial function in paroxysmal AF using three-dimensional speckle tracking technology over the past three years. This study is the first to propose that SGLT2i can improve left atrial function in paroxysmal AF patients with metabolic abnormalities, which is of great significance for preventing heart failure in this type of AF.",[253,254],"Atrial Fibrillation (AF)","Hypertension",[256,257,258],"SGLT2 inhibitor","atrial fibrillation","hypertension","2026-03-15",{"date":261,"type":31},"2026-03-19",{"date":263,"type":31},"2025-03-01",{"date":265,"type":21},"2027-06-30",{"name":37,"class":38},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":71,"phases":276,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":39},"100629060","vorasidenib-guided-by-agx-pet-in-recurrentlow-grade-glioma-100629060","NCT07469735","Vorasidenib Guided by AGX PET in Recurrent\u002FLow-grade Glioma","18F-AGX PET for Evaluation of Vorasidenib Response and Tumor Metabolic Changes in Low-grade IDH-Mutant Glioma","VANGUARD","Inclusion Criteria:\n\n1. Histologically or molecularly confirmed WHO 2021 grade 2 or 3 IDH1\u002F2-mutant diffuse glioma with recurrent or residual disease\n2. At least one measurable non-enhancing lesion (≥1 cm × ≥1 cm) on postoperative T2\u002FFLAIR MRI\n3. Eligible for Vorasidenib treatment\n4. Age ≥18 years\n5. Karnofsky Performance Status (KPS) score ≥80\n6. Adequate hematologic function\n7. Adequate renal function\n8. Adequate hepatic function\n9. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior treatment with radiotherapy, chemotherapy, or IDH inhibitors\n2. Known contraindications to Vorasidenib\n3. Contraindications to PET\u002FCT imaging\n4. Uncontrolled hyperglycemia\n5. Pregnancy or breastfeeding\n6. Inability to undergo repeated intravenous injections\n7. Known hypersensitivity to imaging agents or study-related medications\n8. Use of strong CYP1A2 inhibitors or CYP2C19 or CYP3A substrates with narrow therapeutic index\n9. Any serious comorbid condition that may interfere with study participation or safety",{"count":223,"type":21},[178],"The goal of this prospective, single-arm, open-label clinical trial is to evaluate whether 18F-AGX PET imaging can be used to assess early treatment response and metabolic changes in adult patients with recurrent or residual WHO 2021 grade 2-3 IDH-mutant diffuse glioma receiving Vorasidenib therapy.\n\nIDH-mutant diffuse gliomas often show slow tumor growth, making early treatment response difficult to evaluate using conventional structural imaging such as magnetic resonance imaging (MRI). Clinical endpoints such as progression-free survival (PFS) and overall survival (OS) typically require long follow-up periods to detect treatment effects. Therefore, the development of sensitive and noninvasive imaging methods for early evaluation of therapeutic response is needed.\n\nThis study aims to determine whether metabolic changes detected by 18F-AGX PET during Vorasidenib treatment are associated with tumor structural changes and clinical outcomes.\n\nThe main questions it aims to answer are:\n\n* Whether early changes in tumor metabolic activity measured by 18F-AGX PET, including percentage change in maximum tumor-to-background ratio (TBRmax), are associated with changes in tumor growth rate (TGR) measured by MRI during treatment.\n* Whether early metabolic response detected by 18F-AGX PET imaging after initiation of Vorasidenib treatment can predict subsequent disease progression or tumor growth dynamics.\n\nParticipants enrolled in this study will receive oral Vorasidenib once daily for 12 treatment cycles (28 days per cycle), with dosing based on body weight.\n\nParticipants will:\n\n* Undergo baseline MRI and 18F-AGX PET imaging following surgery for recurrent or residual disease.\n* Receive oral Vorasidenib continuously for 12 cycles.\n* Undergo MRI scans at baseline and during treatment cycles 1, 2, 3, 6, 9, and 12 to assess structural tumor changes.\n* Undergo 18F-AGX PET\u002FCT scans at baseline and during treatment cycles 1, 2, 3, 6, and 12 to assess metabolic tumor activity.\n* Provide serial blood samples for laboratory safety monitoring, including hematologic and biochemical testing.\n* Undergo magnetic resonance spectroscopy (MRS) to quantify intratumoral 2-hydroxyglutarate (2-HG) levels as an indicator of IDH mutation-associated metabolic activity.\n\nParticipants will be followed for imaging-based disease progression using RANO criteria and for treatment-related adverse events during the study period.\n\nThis study will evaluate the feasibility of using 18F-AGX PET imaging as a noninvasive imaging biomarker for early response assessment in IDH-mutant diffuse glioma patients receiving targeted IDH inhibition therapy with Vorasidenib.",[279,280,281],"Glioma","Diffuse Glioma","Recurrent Gliomas",[283,284,285,286],"IDH Mutation","Vorasidenib","Positron Emission Tomography","Treatment Response","2026-03-09",{"date":289,"type":31},"2026-03-13",{"date":291,"type":21},"2026-04-01",{"date":293,"type":21},"2027-12-31",{"name":37,"class":38},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":247,"enrollmentInfo":304,"targetDuration":4,"studyType":71,"phases":306,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":322},"100527846","phase-4-asymptomatic-tb-with-innovative-modified-short-course-regimens-100527846","NCT06153069","Asymptomatic TB With Innovative Modified Short-course Regimens","Clinical Efficacy of a Short-course Regimen for Asymptomatic Tuberculosis in China","SWIFT","Inclusion Criteria:\n\n* 1\\. Age between 14 to 80 years;\n* 2\\. Male or female;\n* 3\\. Willing to provide signed informed consent, or parental consent and participant assent;\n* 4\\. Individuals with respiratory tract specimen (including sputum\u002Fbronchoalveolar lavage fluid\u002Flung tissue) positive for acid-fast bacilli smear\u002Fculture\u002Fmolecular amplification for M. tuberculosis;\n* 5\\. No unexplained TB-suggestive symptoms in the three months prior to screening, including cough lasting more than two weeks, night sweats, fever or weight loss;\n* 6\\. If non-menopausal woman, agree to use or have used effective contraception during treatment.\n\nExclusion Criteria:\n\n* 1\\. Combined extrapulmonary tuberculosis;\n* 2\\. Induviduals with extensive lesion (lesion involvement exceeding 50% or the aggregate diameter of all cavities exceeding 6 cm) ;\n* 3\\. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones;\n* 4\\. Individuals with impaired liver function (alanine transaminase \\[ALT\\] or total bilirubin \\[TBIL\\] more than 2.5 times the upper limit of normal) or combined with liver cirrhosis;\n* 5\\. Hemoglobin is less than 70g\u002FL, or platelet is less than 50\\*10\\^9\u002FL;\n* 6\\. Estimated Glomerular Filtration Rate (eGFR) is less than 30 mL\u002Fmin\u002F1.73m2;\n* 7\\. Known allergic or intolerant to any of the study drugs;\n* 8\\. Pregnant or breast-feeding;\n* 9\\. Prior anti-TB treatment for more than one week in the past six months;\n* 10.Known history of epilepsy, uncontrolled diabetes;\n* 11.For HIV-positive subjects, T-lymphocyte (CD4 cell) counts less than 100 cells\u002Fmm3;\n* 12\\. Unable to tolerant oral treatment.","14 Years",{"count":305,"type":21},426,[307],"PHASE4","This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.",[310],"Tuberculosis",[312,313],"subclinical tuberculosis","shorter treatment","2026-02-08",{"date":316,"type":31},"2026-02-11",{"date":318,"type":31},"2025-11-21",{"date":320,"type":21},"2028-11",{"name":37,"class":38},5,{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":71,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":39},"100621377","the-impact-of-probiotic-intervention-on-the-gut-microbiota-and-bowel-function-100621377","NCT07369830","The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function","The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function of Patients With Prophylactic Ileostomy for Ultra Low Rectal Cancer -a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 18 and 75 years\n2. Ultra low rectal cancer meeting the indication for Intersphincteric Resection (ISR) surgery\n3. Underwent a prophylactic ileostomy\n4. Scheduled for stoma reversal surgery within 6 months after the ISR procedure\n5. Digestive tract reconstruction achieved via either hand-sewn or stapled coloanal anastomosis\n6. Patient has a strong preference for undergoing sphincter-preserving surgery\n7. Capable of understanding and willing to provide signed informed consent\n\nExclusion Criteria:\n\n1. Does not meet the surgical indications for Intersphincteric Resection (ISR)\n2. Presence of multiple primary colorectal malignancies\n3. Patients who have received neoadjuvant radiotherapy\n4. Patients who experience disease progression or death in the postoperative period\n5. Patients who develop severe anastomotic complications postoperatively, such as anastomotic leakage or stenosis\n6. Patients whose actual stoma reversal surgery occurs more than 6 months after the ISR procedure\n7. Patients who require long-term(more than 3 months) use of antibiotics\n8. History of allergy to Clostridium butyricum (live) Tablets (MIYA) or any of its components\n9. Concurrent use of other probiotic during the study period\n10. Coexisting inflammatory bowel disease\n11. History of neurological or psychiatric disorders, including but not limited to Parkinson's disease, Alzheimer's disease, organic brain diseases, stroke, epilepsy, or major psychiatric disorders (e.g., major depressive disorder)\n12. Pregnant or lactating women","75 Years",{"count":332,"type":21},156,[178],"This study aims to propose a novel, easy-to-operate intervention strategy that effectively improves defecation function after stoma reversal and to assess its impact on the gut microbiota.The efficacy and safety of antegrade placement of probiotics into the distal deserted intestine during prophylactic stoma to improve bowel function after stoma reversal were evaluated through randomized controlled clinical trials.Observing the changes in gut microbiota during the prophylactic stoma period, the impact of probiotics on the structure of gut microbiota, and exploring the correlation between gut genera and bowel function after stoma reversal.",[336],"Rectal Cancer",[338,339,340,341,342],"rectal cancer","intersphincteric resection","prophylactic ileostomy","probiotic intervention","bowel function","2026-01-18",{"date":345,"type":31},"2026-01-27",{"date":347,"type":31},"2025-10-15",{"date":349,"type":21},"2029-06-30",{"name":37,"class":38},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":330,"enrollmentInfo":358,"targetDuration":4,"studyType":71,"phases":360,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":39},"100576180","phase-3-obinotuzumab-versus-cyclophosphamide--glucocorticoids-in-primary-membranous-nephropathyblossom-study-100576180","NCT06781944","OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)","A Multicenter, Open- Label, Randomized, Clinical Trial to Investigate the Efficacy and Safety of OBINOTUZUMAB Versus Cyclophosphamide Combined With Glucocorticoids in Patients With Primary Membranous Nephropathy (Blossom Study)","Inclusion Criteria:\n\n* Aged 18～75 years (including 18 and 75)old at the time of signing Informed Consent Form\n* pMN patients diagnosed according to renal biopsy (original biopsy needs to include light, immunofluorescence, and electron microscopy) within 5 years or serum anti-PLA2R antibody (≥14 RU\u002Fml )\n* 24-hour UPCR ≥ 4 g\u002Fg and serum albumin (sALB) \\\u003C 30 g\u002FL,despite being treated with ACEi and\u002For ARB for ≥ 6 months prior to screening, or 24-hour UPCR ≥ 5 g\u002Fg and sALB \\\u003C 30 g\u002FL , despite being treated with ACEi and\u002For ARB for ≥ 3 months prior to screening; or 24-hour UPCR ≥ 8 g\u002Fg and sALB \\\u003C 25 g\u002FL, despite being treated with ACEi and\u002For ARB for ≥ 1 month prior to screening,.\n* eGFR ≥40 mL\u002Fmin\u002F1.73m2 (CKD-EPI), a renal biopsy is required to exclude renal damage due to other co-morbidities if eGFR \\\u003C60mL\u002Fmin\u002F1.73 m2.\n* Ability to comply with the study protocol, in the investigator's judgment\n\nExclusion Criteria:\n\n* Patients with a secondary cause of MN (e.g. hepatitis B, systemic lupus erythematosus, medications, malignancies)\n* Type 1 or 2 diabetes mellitus\n* eGFR \\\u003C40 mL\u002Fmin\u002F1.73m2 (CKD-EPI) or dialysis or kidney transplantation\n* Evidence of 50% reduction in proteinuria or serum anti-PLA2R antibody within 6 months prior to screening",{"count":359,"type":21},144,[361],"PHASE3","This is a randomized, parallel group, active-controlled, open-label, Phase III study comparing the efficacy and safety of obinutuzumab versus cyclophosphamide combined with glucocorticoids in patients with primary membranous nephropathy (pMN). Approximately 144 patients with pMN who have been diagnosed by biopsy or serum anti-PLA2R antibody will be enrolled.\n\nIntervention: Intravenous infusion of 1,000 mg obinutuzumab at weeks 0, 2, 24 and 26 Comparator: Cyclical cyclophosphamide and glucocorticoids Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg\u002Fkg\u002Fd (max 40 mg\u002Fd) for 27 days.\n\nOral cyclophosphamide will be given for 30 days in month 2, 4, 6.",[364],"Primary Membranous Nephropathy","2026-01-16",{"date":367,"type":31},"2026-01-21",{"date":369,"type":31},"2024-10-23",{"date":371,"type":21},"2028-05-31",{"name":37,"class":38},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":71,"phases":383,"briefSummary":385,"conditions":386,"keywords":391,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":4},"100619223","phase-1-a-study-of-c-car168-in-the-treatment-of-central-nervous-system-autoimmune-diseases-refractory-to-standard-therapy-100619223","NCT07341828","A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","An Exploratory Clinical Study of Anti-CD20\u002FB-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as Multiple Sclerosis (MS)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FAutoimmune Encephalitis(AiE)\u002FStiff Person Spectrum Disorder(SPSD) according to recognized diagnostic criteria for at least 6 months.\n* Prior treatment failure with standard therapy.\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.\n* Any contraindication to lumbar puncture.","70 Years",{"count":382,"type":21},15,[384],"PHASE1","This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy",[387,388,389,390],"Multiple Sclerosis (MS)","Neuromyelitis Optica Spectrum Disorders (NMOSD)","Autoimmune Encephalitis","Stiff Person Syndrome",[392],"CD20\u002FBCMA-directed CAR-T cells","2026-01-13",{"date":395,"type":31},"2026-01-15",{"date":397,"type":21},"2026-02",{"date":399,"type":21},"2029-02",{"name":37,"class":38},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":71,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":167},"100592557","phase-3-chinese-ischemic-stroke-beyond-45-hours-with-tenecteplase-under-optimized-non-contrast-ct-selection-100592557","NCT06994975","CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection","CHESTNUT","Inclusion Criteria:\n\n1. Suspected acute ischemic stroke of anterior cerebral circulation.\n2. Last known well time \\>4.5 hours.\n3. Age ≥18 years old.\n4. Baseline NIHSS (National Institutes of Health Stroke Scale) score \\>5.\n5. Premorbid modified Rankin Scale (mRS) ≤1.\n6. Imaging criteria: Automated infarct segmentation by NCCT post-processing model indicates infarct core volume \\\u003C50 mL with no visible hypodensity in \\>1\u002F3 of the MCA territory.\n7. Informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Obvious hypodensity on NCCT deemed related with the current stroke event, with no expected benefit from thrombolysis as assessed by the investigators\n2. Endovascular thrombectomy (EVT) planned at the time of randomization\n3. Allergy to the test drug and its ingredients\n4. Rapidly improving symptoms at the discretion of the investigator\n5. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT\n6. History of any intracranial hemorrhage\n7. History of ischemic stroke or major head trauma within the last 3 months\n8. History of intracranial\u002Fintraspinal surgery during the last 3 months\n9. Gastrointestinal malignancy or gastrointestinal bleeding within 21 days\n10. Known bleeding diatheses; platelets count \\\u003C 100000\u002Fmm3, international normalized ratio \\> 1.7, prothrombin time \\> 15 s, or activated partial thromboplastin clotting time \\> 40 s\n11. Treatment with a full dosage of low-molecular weighted heparin in the last 24 hours\n12. Treatment with direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal\n13. Initial systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg\n14. Initial glucose levels \\\u003C2.8 or 22.22 mmol\u002FL\n15. Known or suspected aortic arch dissection\n\nIn addition to:\n\n1. Clinical presentation or imaging profile consistent with Moyamoya disease\u002Fsyndrome.\n2. Pregnancy or breastfeeding.\n3. Recent participation in another investigational drug or device study or registry in the past 30 days before enrollment.\n4. Any terminal illness such that the patient would not be expected to survive more than three months.\n5. Other conditions in which investigators believe that participating in this study may be harmful to the patient.",{"count":409,"type":21},890,[361],"The CHESTNUT trial is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial. The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg\u002Fkg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without substantial infarction on non-contrast computed tomography (NCCT) in an extended time window.",[413],"Acute Ischemic Stroke","2025-12-22",{"date":416,"type":31},"2025-12-30",{"date":418,"type":31},"2025-11-03",{"date":420,"type":21},"2028-06",{"name":37,"class":38},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":429,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":71,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":447},"100517792","phase-3-tb-youth---tb-systemic-management-using-one-month-ultra-short-tpt-regimen-for-school-contacts-100517792","NCT06022146","TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts","TB-YOUTH","Inclusion Criteria:\n\n1. Aged ≥13 years and body weight ≥ 30 kg;\n2. School-registered individuals including:\n\n   * Currently attending junior \u002F senior high school or university students;\n   * School staff members;\n3. Close contacts of active pulmonary TB index cases (confirmed or clinically diagnosed) within the school, defined by meeting both of the following:\n\n   * Teachers\u002Fstudents sharing the same classroom or dormitory with the index case;\n   * Exposure history: Prolonged sharing of enclosed space (\\>4 hours total within 1 week) with the index case;\n4. Confirmed LTBI status through screening;\n5. Voluntary participation with signed informed consent form (for adults ≥18 years);\n6. Parental \u002F guardian consent and co-signed informed consent form (for minors aged 13-17 years).\n\nExclusion Criteria:\n\n1. Current active TB disease (clinically or bacteriologically confirmed);\n2. Documented isoniazid\u002Frifampicin resistance in the corresponding M. tuberculosis strain from the index case;\n3. Self-reported use of rifamycins (e.g., rifampicin, rifapentine) or isoniazid for \\>14 consecutive days within the past 2 years;\n4. Prior completion of full-course of treatment for ATB or LTBI;\n5. Hypersensitivity or intolerance to rifamycins (rifapentine \u002F rifampicin) or isoniazid;\n6. HIV positive serostatus or AIDS patients;\n7. History of viral hepatitis (e.g., chronic hepatitis B, chronic hepatitis C) or liver cirrhosis;\n8. Liver dysfunction (TBil\\>2.5mg\u002FdL \\[43umol\u002FL\\] or ALT \u002F AST\\>2ULN) or renal dysfunction.\n9. Current receiving immunosuppressive therapy or biological agents.\n10. Hematologic disorders with either PLT\\\u003C50×109\u002FL or WBC\\\u003C3.0×109\u002FL.\n11. Other conditions deemed unsuitable for TPT by investigators.","13 Years",{"count":431,"type":21},3520,[361],"This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.",[310,435],"Latent Tuberculosis",[437,438,439],"latent tuberculosis","TPT","active screening","2025-12-15",{"date":414,"type":31},{"date":443,"type":31},"2023-09-01",{"date":445,"type":21},"2026-09-01",{"name":37,"class":38},47,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":330,"enrollmentInfo":454,"targetDuration":4,"studyType":71,"phases":456,"briefSummary":457,"conditions":458,"keywords":461,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":167},"100584970","study-on-the-effectiveness-and-safety-of-temporal-interference-stimulation-in-treating-patients-with-severe-consciousness-disorders-100584970","NCT06896279","Study on the Effectiveness and Safety of Temporal Interference Stimulation in Treating Patients With Severe Consciousness Disorders","Inclusion Criteria:\n\n* Severe consciousness disorder patients aged 18 to 75 years old, regardless of gender;\n* Patients with severe consciousness disorders, namely a minimally conscious state or vegetative state that lasts for 28 days or more;\n* Patients with normal body temperature, stable vital signs, spontaneous breathing, tracheotomy without the use of a metal cannula and with a small amount of sputum, and who are eligible for magnetic resonance imaging (MRI) examination;\n* Written informed consent obtained from the patient's family members in advance.\n\nExclusion Criteria:\n\n* Individuals with a previous history of significant neuropsychiatric and other major disorders such as those involving the heart, lung, liver, and kidney;\n* Those who have undergone V-P shunt or Ommaya reservoir implantation and other procedures that may influence the analysis of magnetic resonance scanning signals;\n* Patients who are scheduled for V-P shunt or Ommaya reservoir implantation in the near future;\n* Pregnant women;\n* Those who have participated in other drug or device clinical trials;\n* Patients with poorly controlled epilepsy in the recent period;\n* Those with infections at the TI stimulation site or compromised skin integrity at the electrode placement site;\n* Those currently taking medications prone to inducing epilepsy, such as quinolone drugs;\n* Those with intracranial infections, intracranial tumors, or metallic objects within the cranium;\n* Those allergic to electrode gel or adhesives;\n* Those with implanted electronic devices within the body;\n* Those with severe cardiac disorders and those equipped with cardiac pacemakers.",{"count":455,"type":21},20,[178],"Investigating the efficacy and safety of temporal interference stimulation for patients with disorders of consciousness.",[459,460],"Disorder of Consciousness","Temporal Interference Stimulation",[459,462,460],"Randomized clinical trail","2025-12-08",{"date":465,"type":31},"2025-12-16",{"date":467,"type":31},"2025-04-21",{"date":469,"type":21},"2026-05-17",{"name":37,"class":38},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":479,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":39},"100431297","long-term-outcomes-of-anti-viral-therapies-in-patients-with-chronic-viral-hepatitis-b-100431297","NCT04896255","Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B","Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B: A Multicenter, Real-world Study","OASIS","Inclusion Criteria:\n\n* Male and female patients with age ≥18; subjects who are over 70 years of age must be in generally stable health conditions.\n* There should be evidences that HBsAg has been positive for more than 6 months or HBV-related histological changes.\n* Planned or currently receiving potent low-resistance NAs \\[entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)\\], or planned to receive PegIFNα-2b, either treated or treatment-naïve.\n* Agree to participate in the study and sign the patient informed consent form.\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma (diagnosed or planned for treatment) or liver failure at baseline\n* Concurrently participating in other interventional clinical trials.\n* Any other conditions deemed unsuitable by investigators or preventing compliance with study requirements.",{"count":480,"type":21},33000,"The goal of this observational, multicenter , real-world study is to evaluate the long-term outcomes of different antiviral therapies in adults with chronic hepatitis B (CHB). The main questions it aims to answer are: What is the 5-year incidence of hepatocellular carcinoma (HCC) under various treatment regimens? How do rates of HBsAg seroclearance, decompensated cirrhosis, liver fibrosis progression, and other virological and clinical outcomes compare across regimens? Researchers will compare real-world treatment arms-including nucleos(t)ide analogue (NA) monotherapy (e.g., entecavir, tenofovir), PegIFN based regimen (e.g., PegIFN monotherapy, PegIFN plus NA combinations)-to identify optimal strategies for reducing HCC risk and improving functional cure rates.\n\nParticipants will undergo routine clinical care with no study-imposed interventions; data on demographics, medical history, symptoms, laboratory tests (e.g., HBsAg, HBV DNA, liver function), imaging (e.g., ultrasound, elastography), and clinical events will be collected prospectively (for up to 5 years in some cohorts) or retrospectively from medical records at baseline and scheduled follow-up visits (e.g., every 3-12 months initially, then annually).",[483],"Chronic Hepatitis b","2025-09-30",{"date":486,"type":31},"2025-10-06",{"date":488,"type":31},"2020-09-09",{"date":490,"type":21},"2031-12-31",{"name":37,"class":38},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":16,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":499,"targetDuration":501,"studyType":23,"phases":4,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":39},"100563576","evaluation-of-two-cell-based-assays-for-diagnosing-mog-igg-associated-disorders-100563576","NCT06617962","Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders","Evaluation of The Diagnostic Value of Two Cell-based Assays for MOG-IgG-associated Diseases: A Multicenter, Paired Design Observational Study","Inclusion Criteria:\n\n* age ≥18 years old, male and female.\n* MOGAD is highly suspected.\n* Other inflammatory CNS disease control groups include: According to the diagnostic criteria and consensus of various diseases, the diagnosis of multiple sclerosis, Autoimmune encephalitis (except NMDAR encephalitis), Guillain-Barre syndrome (GBS), Chronic Inflammatory Demyelinating polyradiculopathy (CIDP), Retinal Cerebrovascular disease (SUSAC), POEMS syndrome (POEMS), and neuropathy were confirmed. The monoclonal gammopathy of unknown significance (MGUS), Sarcoidosis and so on.\n* The control group of non-inflammatory central nervous system diseases included: Migraine, CSVD, benign cranial hypertension, Glioma with definite diagnosis and no other autoimmune diseases.\n* Healthy controls include healthy people who have no autoimmune diseases through physical examination and other means.\n* Complete clinical data.\n* Informed consent of the patient or his guardian has been obtained.\n\nExclusion Criteria:\n\n* According to the Guidelines for Diagnosis and Treatment of Optic Neuromyelitis Spectrum Diseases (2021), patients with optic Neuromyelitis Spectrum diseases (NMOSD) with positive AQP4 were clearly diagnosed.\n* According to the Expert Consensus on the Diagnosis and Treatment of Autoimmune encephalitis in China (2022), the diagnosis was confirmed as NMDAR encephalitis.\n* Patients with positive anti-glial fibrillary acidic protein antibody (GFAP-IgG) in serum and\u002For cerebrospinal fluid.\n* Lack of clinical data.\n* Unqualified blood samples.\n* The patient\\'s informed consent was not obtained.\n* Misdiagnosis in the research process went wrong in this study.",{"count":500,"type":21},240,"30 Days","Anti-myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD) is a rare inflammatory autoimmune disease. In addition, since the international MOGAD group proposed live-cell based assays for MOGAD diagnosis in 2023, there are still no real-world cohort validation studies on this methodology. This study intends to establish a large sample cohort with multi-center and paired design. MOG-IgG detection based on live cells and fixed cells was performed on the study participants with high suspicion of MOGAD and the negative control population, to obtain the diagnostic performance parameters and consistency evaluation of the two methodologies, evaluate their clinical diagnostic value, and explore the best individual assay cutoffs for MOG-IgG detection suitable for the diagnosis of MOGAD in China.",[504],"Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders","2025-09-29",{"date":507,"type":31},"2025-10-01",{"date":509,"type":31},"2024-11-18",{"date":511,"type":21},"2025-12-01",{"name":37,"class":38},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":521,"targetDuration":523,"studyType":23,"phases":4,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":167},"100335598","the-national-registry-study-for-the-real-world-patients-with-parkinsonian-disorders-in-china-100335598","NCT03649503","The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China","The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China (ForPDCN)","ForPDCN","Inclusion Criteria:\n\nAnyone with Parkinsonian Disorders is welcome to join the Registry.\n\nExclusion Criteria:",{"count":522,"type":21},100000,"10 Years","The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in this study. Participants will enroll through a platform named PaWei, and provide informed consent prior to any study activities. PaWei will collect a variety of information, including participants' demographic information, overall health, family history of Parkinson's Disease, other clinical information (clinical drug use, drug efficacy, and comorbid disorders), mood status, sleep, diet, exercise, memory complaints, online cognitive tests, the Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8), Movement Disorder Society-Unified Parkinson's Disease Rating Scale IB \\& II (MDS-UPDRS IB \\& II), Non-Motor Symptom Aassessment Scale for Parkinson's Disease (NMSS) , Hoehn and Yahr Scale, and other scales related to quality of life, etal---all through self-reported online questionnaires. Participants will also be asked to return to the PaWei every 3 months at regular intervals, to complete follow-up scales related to quality of life, and neuropsychological assessments, etal. Anyone with Parkinsonian Disorders is welcome to participate.",[526],"Parkinsonian Disorders",[528,529,530,531,532],"Brain Health","Brain Research","parkinsonism","prospective cohort study","large sample size",{"date":534,"type":31},"2025-10-02",{"date":536,"type":31},"2018-10-01",{"date":538,"type":21},"2033-09-30",{"name":37,"class":38},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":330,"enrollmentInfo":547,"targetDuration":4,"studyType":71,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":557,"leadSponsor":559,"locationsCount":167},"100607193","phase-2-orelabrutinib-combined-with-teniposide-rituximab-and-methotrexate-for-newly-diagnosed-pcnsl-100607193","NCT07185373","Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL","Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed Primary Central Nervous System Lymphoma-A Randomized Controlled Trial","Inclusion Criteria:\n\n* No prior systemic treatment for primary central nervous system lymphoma\n* Pathologically confirmed as diffuse large B-cell lymphoma subtype; with sufficient residual surgical specimens remaining after meeting the needs for pathological diagnosis and preservation\n* Aged 18-75 years (inclusive)\n* ECOG performance status ≤3\n* Expected survival time exceeding 3 months\n* Major organ functions meeting the following standards:\n\n  1. Blood routine parameters (without growth factor support or blood transfusion within the past 7 days; 14 days for pegylated myeloid growth factors): absolute neutrophil count (ANC) ≥1.0×10⁹\u002FL, platelet count (PLT) ≥75×10⁹\u002FL, hemoglobin (Hb) ≥80g\u002FL;\n  2. Blood biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) or ≤3×ULN (for confirmed Gilbert syndrome with direct bilirubin within normal range); aspartate transaminase (AST) or alanine transaminase (ALT) ≤2.5×ULN; serum creatinine within normal range; estimated glomerular filtration rate (eGFR) ≥70ml\u002Fmin;\n  3. Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n* Ability to tolerate lumbar puncture and\u002For having an indwelling Ommaya reservoir\n* Peripheral blood flow cytometry showed no clonal B cells and no other extramedullary lesions.\n* Voluntary signing of a written informed consent form by the participant or their legal representative prior to trial screening, indicating their understanding of the study purpose, necessary procedures, and willingness to comply with the protocol and attend follow-up visits\n\nExclusion Criteria:\n\n* Lymphoma involving sites outside the central nervous system (CNS)\n* Patients with a previous history of tumors\n* Patients with intraocular lymphoma or suspected diagnosis of intraocular lymphoma invasion\n* Uncontrolled or significant cardiovascular diseases, including:\n\n  1. New York Heart Association (NYHA) class Ⅲ-Ⅳ congestive heart failure, unstable angina, myocardial infarction within 6 months prior to the first administration of study drugs; clinically significant or treatment-requiring arrhythmias at screening; left ventricular ejection fraction (LVEF) \\\u003C50%; or patients with controlled coronary heart disease who are either not using anticoagulants\u002Fantiplatelet drugs or taking 2 or more anticoagulants\u002Fantiplatelet drugs orally.\n  2. Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy).\n  3. A history of clinically significant QTc interval prolongation, or QTc interval (calculated via Bazett's formula using manually collected screening data) \\>470ms in females or \\>450ms in males.\n  4. Refractory hypertension (blood pressure not controlled despite ≥1 month of optimal, tolerable doses of 2 or more antihypertensive drugs \\[including diuretics\\] with lifestyle modifications; or blood pressure controlled only with 3 or more antihypertensive drugs).\n* Active bleeding within 2 months prior to screening; use of anticoagulants\u002Fantiplatelet drugs for \\\u003C6 months; or a definite bleeding tendency as judged by the investigator (e.g., bleeding-risk esophageal varices, active local ulcer lesions).\n* Diabetic patients whose blood sugar remains poorly controlled after insulin treatment\n* A history of stroke or intracranial hemorrhage within 6 months prior to screening, excluding postoperative sequelae-related intracranial hemorrhage\n* A history of organ transplantation or allogeneic bone marrow transplantation\n* Surgical procedures within 6 weeks prior to screening (diagnostic examinations are not considered surgical procedures; insertion of vascular access devices is exempt from this exclusion criterion).\n* Use of Chinese herbal medicines with anti-tumor effects (as specified in the package insert, e.g., Compound Cantharidin Capsules) within 4 weeks prior to screening\n* Active or uncontrolled hepatitis B virus (HBV) infection (HBsAg positive and\u002For HBcAb positive with positive HBV DNA titer); HCV Ab positive; HIV positive. The following patients can be provisioned for continuous observation pending enrollment when given prophylactic anti-HBV (such as entecavir or tenofovir), including :\n\n  1. HBsAg positive with negative HBV DNA titer.\n  2. HBsAg negative, HBsAb negative, HBcAb positive, and negative HBV DNA titer Patients with positive HBV-DNA can be considered for enrollment only when the HBV-DNA value is less than 500IU\u002FmL after treatment\n* Uncontrolled active systemic fungal, bacterial, viral, or other infections (defined as persistent infection-related symptoms\u002Fsigns that do not improve despite appropriate antibiotic or other treatments) or requiring intravenous antibiotics\n* Administration of live vaccines or immunological agents within 4 weeks prior to enrollment.\n* Need for concurrent and continuous use of drugs with moderate\u002Fstrong inhibitory or inductive effects on cytochrome P450 CYP3A.\n* Patients with hypersensitivity to orelabrutinib or its excipients (e.g., immediate or accelerated allergic reactions).\n* Patients with hypersensitivity to teniposide or its excipients (e.g., immediate or accelerated allergic reactions)\n* Clinically significant gastrointestinal abnormalities that may affect drug intake, transit, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or participants with total gastrectomy.\n* Participants with a history or current presence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia with severely impaired lung function, etc\n* Participants with chronic liver damage, severe fatty liver, or alcoholic liver disease.\n* Pregnant or lactating women; women of childbearing age who are unwilling to use contraception from the time of enrollment until 180 days after the last dose of the study drug (serum pregnancy test results must be negative within 14 days before the start of study drug treatment for women of childbearing potential); men who are not surgically sterilized and unwilling to use contraception during the study and until 180 days after the last dose of the study drug.\n* Presence of life-threatening diseases or severe organ dysfunction, deemed unsuitable for participation in the trial by the investigator.\n* Any mental or cognitive impairment that may limit the understanding and execution of the informed consent form or adherence to the study\n* Previous receipt of whole-brain radiotherapy for primary central nervous system lymphoma.",{"count":548,"type":21},215,[73,361],"This is a three-arm, multicenter, randomized controlled trial. Eligible participants will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio.\n\nInduction regimens:\n\nArm A: Teniposide + orelabrutinib + rituximab + methotrexate (MTX) + dexamethasone, administered in 21-day cycles.\n\nArm B: Orelabrutinib + rituximab + MTX + dexamethasone, administered in 21-day cycles.\n\nArm C: Rituximab + MTX + dexamethasone, administered in 21-day cycles. Participants achieving complete response (CR) or unconfirmed complete response (CRu) post-induction will proceed to consolidation therapy, with options including: MTX + rituximab (once every 3 months for 1 year); high-dose chemotherapy followed by autologous stem cell transplantation (ASCT); dose-reduced whole brain radiotherapy; or other modalities (as determined by the investigator).",[552],"Primary Central Nervous System Lymphoma","2025-09-15",{"date":555,"type":31},"2025-09-22",{"date":507,"type":21},{"date":558,"type":21},"2029-07-30",{"name":37,"class":38},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":247,"enrollmentInfo":567,"targetDuration":569,"studyType":23,"phases":4,"briefSummary":570,"conditions":571,"keywords":575,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":167},"100568880","pdo-based-drug-sensitive-test-in-rm-sgc-100568880","NCT06686979","PDO Based Drug Sensitive Test in R\u002FM SGC","Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent\u002FMetastatic Salivary Gland Cancer: A Prospective, Multicenter, Observational Study","Inclusion Criteria:\n\n* Pathologically confirmed R\u002FM SGC patients\n* Tumor tissues available for organoid culture\n* ECOG score: 0-2 points\n* Life expectancy \\> 3 months\n* Normal major organ function, tolerable to chemotherapy, targeted therapy, immunotherapy: a. Hematology examination criteria must meet: WBC≥4.0×109\u002FL, ANC≥1.5×109\u002FL, PLT≥80×109\u002FL, Hb≥90 g\u002FL (no blood transfusion or blood products within 14 days, no use of G-CSF or other hematopoietic growth factors); b. Biochemical examination must meet the following criteria: serum albumin≥3.0 g\u002FdL (30 g\u002FL), TBIL≤1.5×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance≥60 ml\u002Fmin (Cockcroft-Gault formula); c. Good coagulation function: defined as International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5 times ULN; if the study participant is on anticoagulant therapy, as long as PT is within the intended range of the anticoagulant medication\n* Able to understand the content of informed consent form, sign the informed consent form, and willing to cooperate with the follow-up\n\nExclusion Criteria:\n\n* Metastatic tumors in the head and neck region, or non-salivary gland cancer tumors such as sarcoma, squamous cell carcinoma, nasopharyngeal carcinoma, etc.\n* Known allergy to the study drugs or their active ingredients or any excipients; or had a severe allergic reaction to other monoclonal antibodies\n* Pregnant or breastfeeding female patients; or women of childbearing age with positive pregnancy test results (serum or urine) within 7 days before enrollment, or negative results but refusing to use effective contraception during the study period and 2 months after the last administration of study medication; or male patients with partners of childbearing age, refusing to use effective contraception during the study period and 2 months after the last administration of study medication\n* Severe liver diseases (such as cirrhosis), kidney diseases, respiratory system diseases, hematopoietic system diseases, or endocrine system diseases, uncontrolled diseases\n* Infected with HIV, active hepatitis B (HBV-DNA≥104 copies\u002Fml) or hepatitis C (hepatitis C antibody positive, and HCR-RNA above the lower limit of detection of the analytical method), uncontrolled diseases\n* Within 6 months before enrollment, the following conditions occurred: myocardial infarction, severe\u002Funstable angina, NYHA class 2 or above heart failure, clinically significant supraventricular or ventricular arrhythmias, and symptomatic congestive heart failure, uncontrolled diseases\n* Patients with mental illness or known history of psychiatric drug abuse or drug addiction\n* Unable to give consent, unable to obtain the required amount of tumor tissue for the study\n* Other serious physical or mental diseases or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the study results; or any other situation that the researchers deem unsuitable for participation in this study",{"count":568,"type":21},40,"2 Years","To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R\u002FM SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.",[572,573,574],"Salivary Gland Cancers","Patient Derived Organoid","Drug Sensitive Test in Vitro",[576,577,578],"Recurrent\u002Fmetastatic salivary gland cancer","Patient-derived organoid","Drug sensitive test in vitro","2025-08-26",{"date":581,"type":31},"2025-09-03",{"date":583,"type":31},"2025-03-26",{"date":585,"type":21},"2028-11-30",{"name":37,"class":38},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":247,"enrollmentInfo":594,"targetDuration":569,"studyType":23,"phases":4,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":603,"leadSponsor":605,"locationsCount":167},"100568831","pdo-based-drug-sensitive-test-in-rm-hnscc-100568831","NCT06686342","PDO Based Drug Sensitive Test in R\u002FM HNSCC","Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma: A Prospective, Multicenter, Observational Study","Inclusion Criteria:\n\n* Pathologically confirmed R\u002FM HNSCC patients\n* Tumor tissues available for organoid culture\n* ECOG score: 0-2 points\n* Life expectancy \\> 3 months\n* Normal major organ function, tolerable to chemotherapy, targeted therapy, immunotherapy: a. Hematology examination criteria must meet: WBC≥4.0×109\u002FL, ANC≥1.5×109\u002FL, PLT≥80×109\u002FL, Hb≥90 g\u002FL (no blood transfusion or blood products within 14 days, no use of G-CSF or other hematopoietic growth factors); b. Biochemical examination must meet the following criteria: serum albumin≥3.0 g\u002FdL (30 g\u002FL), TBIL≤1.5×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance≥60 ml\u002Fmin (Cockcroft-Gault formula); c. Good coagulation function: defined as International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5 times ULN; if the study participant is on anticoagulant therapy, as long as PT is within the intended range of the anticoagulant medication\n* Able to understand the content of informed consent form, sign the informed consent form, and willing to cooperate with the follow-up\n\nExclusion Criteria:\n\n* Metastatic tumors in the head and neck region, or non-HNSCC such as sarcoma, adenocarcinoma, nasopharyngeal carcinoma, etc.\n* Known allergy to the study drugs or their active ingredients or any excipients; or had a severe allergic reaction to other monoclonal antibodies\n* Pregnant or breastfeeding female patients; or women of childbearing age with positive pregnancy test results (serum or urine) within 7 days before enrollment, or negative results but refusing to use effective contraception during the study period and 2 months after the last administration of study medication; or male patients with partners of childbearing age, refusing to use effective contraception during the study period and 2 months after the last administration of study medication\n* Severe liver diseases (such as cirrhosis), kidney diseases, respiratory system diseases, hematopoietic system diseases, or endocrine system diseases, uncontrolled diseases\n* Infected with HIV, active hepatitis B (HBV-DNA≥104 copies\u002Fml) or hepatitis C (hepatitis C antibody positive, and HCR-RNA above the lower limit of detection of the analytical method), uncontrolled diseases\n* Within 6 months before enrollment, the following conditions occurred: myocardial infarction, severe\u002Funstable angina, NYHA class 2 or above heart failure, clinically significant supraventricular or ventricular arrhythmias, and symptomatic congestive heart failure, uncontrolled diseases\n* Patients with mental illness or known history of psychiatric drug abuse or drug addiction\n* Unable to give consent, unable to obtain the required amount of tumor tissue for the study\n* Other serious physical or mental diseases or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the study results; or any other situation that the researchers deem unsuitable for participation in this study",{"count":595,"type":21},100,"To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R\u002FM HNSCC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.",[598,573,574],"Head and Neck Squamous Cell Carcinoma",[600,577,578],"Recurrent\u002Fmetastatic head and neck squamous cell carcinoma",{"date":581,"type":31},{"date":583,"type":31},{"date":604,"type":21},"2028-11-11",{"name":37,"class":38},""]